BioCentury
ARTICLE | Clinical News

ALV003: Phase IIb started

November 4, 2013 8:00 AM UTC

Alvine began the double-blind, placebo-controlled, dose-ranging, international Phase IIb CeliAction Study to evaluate oral ALV003 for 12 weeks in about 500 patients with celiac disease who are symptom...